Cost-effective detection of non-antidouble-stranded DNA antinuclear antibody specificities in daily clinical practice
Authors:
- P. A. J. M. VosPVP. A. J. M. Vos
- E. J. E. G. BastEBE. J. E. G. Bast
- R. H. W. M. DerksenRDR. H. W. M. Derksen
Open Access
- 20 December 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (5) , 629-635
Abstract
Objectives. To compare the utility of indirect immunofluorescence for the detection of antinuclear antibodies (ANA-IIF) and a fully automated test (ELiA Symphony™) that detects antibodies against a mixture of nuclear and cytoplasmic antigens (ENA), to select sera that should be tested for non-antidouble-stranded DNA (dsDNA) antinuclear antibodies in a relatively expensive automated line immunoassay (INNO-LIA™ANA update, Lineblot). Methods. All 328 sera sent to the laboratory for ANA or anti-ENA tests, over a 4 month period were evaluated in all three assays. Results were related to signs and symptoms of systemic autoimmune disease (AID) that patients had before or at the time of blood sampling. Results. Overall, 72 (22%) sera were Lineblot positive. Of 198 patients without clinical manifestations of AID, 7% were Lineblot positive. Limiting Lineblot to sera positive in either ANA-IIF or Symphony tests failed to detect 26 (ANA-IIF) and 22 (Symphony) Lineblot-reactive sera, with 15 sera being negative in both assays. From a clinical point of view, failure to detect these reactivities was not important in most cases. Conclusions. Restriction of performance of Lineblot to patients with at least one criterion for AID is an ideal and cost-effective strategy. In ignorance of clinical signs and symptoms, screening of sera by ANA-IIF or Symphony strongly reduces the costs of anti-ENA detection, with minimal loss in diagnostic capacity. Based on small differences, including the fact that anti-dsDNA antibodies give a positive ANA-IIF, we prefer screening with ANA-IIF over Symphony.Keywords
This publication has 9 references indexed in Scilit:
- Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay systemLupus, 2003
- Detection of Specific Antinuclear Reactivities in Patients with Negative Anti-nuclear Antibody Immunofluorescence Screening TestsClinical Chemistry, 2002
- Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIAr ANA Update for the detection of autoantibodies in connective tissue disordersArthritis Research & Therapy, 2002
- Antinuclear Antibody TestingArchives of internal medicine (1960), 1996
- Rapid and sensitive detection of anti-ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectantsPathology, 1996
- The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseasesJournal of Immunological Methods, 1991
- The Anticentromere Antibody: Disease Specificity and Clinical SignificanceMayo Clinic Proceedings, 1984
- Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)The American Journal of Medicine, 1972